Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Helsinn’s renewed focus on developing highly innovative oncology assets to address unmet needs, and this license agreement with Juniper, will ensure that Truseltiq (infigratinib), is accessible to patients in Australia, Southeast Asia and certain marke...
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 05, 2022
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, the registeration, distribution, promotion, market and sell LEDAGA® (chlormethine gel) in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”) in adults.
Product Name : Ledaga
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 09, 2022
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
